Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial

GR Burmester, AJ Kivitz, H Kupper… - Annals of the …, 2015 - ard.bmj.com
Objective CONCERTO was a randomised, double-blind, parallel-armed study of
methotrexate (MTX) in combination with adalimumab to assess whether an increasing trend …

Longterm effect of delaying combination therapy with tumor necrosis factor inhibitor in patients with aggressive early rheumatoid arthritis: 10-year efficacy and safety of …

EC Keystone, FC Breedveld, D van der Heijde… - The Journal of …, 2014 - jrheum.org
Objective. To evaluate the longterm safety of adalimumab administered with or without
methotrexate (MTX) and compare the efficacy of combination therapy initialization to …

Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission

D Aletaha, X Wang, S Zhong, S Florentinus… - Seminars in arthritis and …, 2020 - Elsevier
Objectives In patients with rheumatoid arthritis (RA), remission may be assessed by various
composite measures. We assessed achievement of remission as defined by Boolean …

Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis

D Aletaha, JF Maa, S Chen, SH Park… - Annals of the …, 2019 - ard.bmj.com
Objectives To determine if disease duration and number of prior disease-modifying
antirheumatic drugs (DMARDs) affect response to therapy in patients with established …

Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with …

JS Smolen, RF van Vollenhoven… - Annals of the …, 2018 - ard.bmj.com
Objectives Methotrexate is considered to be first-line therapy for rheumatoid arthritis (RA).
However, a substantial proportion of treated patients do not achieve the desired goals of …

[HTML][HTML] Is new drug prescribing in primary care specialist induced?

SR Florentinus, ER Heerdink, L van Dijk… - BMC health services …, 2009 - Springer
Background Medical specialists are often seen as the first prescribers of new drugs.
However, the extent to which specialists influence new drug prescribing in primary care is …

Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early …

A Kavanaugh, RF van Vollenhoven… - Annals of the …, 2018 - ard.bmj.com
Objectives To compare responses in patients with early rheumatoid arthritis (RA) initially
treated with the tumour necrosis factor inhibitor (TNFi) adalimumab+ methotrexate (MTX) …

The effect of pharmacotherapy audit meetings on early new drug prescribing by general practitioners

SR Florentinus, R Hulten, MEM Kloth… - Annals of …, 2007 - journals.sagepub.com
Background: New drugs are cornerstones of clinical practice. However, when included in
practice in an erratic fashion, there is valid concern about uncertain risk–benefit for patients …

Low hemoglobin and radiographic damage progression in early rheumatoid arthritis: secondary analysis from a phase III trial

B Möller, J Everts‐Graber, S Florentinus… - Arthritis care & …, 2018 - Wiley Online Library
Objective To study low blood hemoglobin concentrations as a predictor of radiographic
damage progression in patients with rheumatoid arthritis (RA). Methods Post hoc analyses …

Final 10-year effectiveness and safety results from study DE020: adalimumab treatment in patients with rheumatoid arthritis and an inadequate response to standard …

DE Furst, A Kavanaugh, S Florentinus, H Kupper… - …, 2015 - academic.oup.com
Objective. To evaluate the long-term effectiveness and safety of 10 years of adalimumab
(ADA) treatment in DMARD-refractory RA patients and to analyse efficacy based on RF …